Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety
- PMID: 22824056
- DOI: 10.1016/j.parkreldis.2012.06.022
Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety
Abstract
Enterally administered levodopa/carbidopa gel (Duodopa®) is used for the treatment of advanced Parkinson's disease (PD) in patients with motor fluctuations and dyskinesias. This review summarizes the current efficacy and safety data on this drug. Clinically important differences (CID) have been used to assess whether statistical improvements in symptoms translate into meaningful improvements for the patients. A PubMed search in February 2012 found 23 papers with efficacy data and 33 with safety data. Of 11 studies reporting Unified Parkinson's Disease Rating Scale (UPDRS) III scores, 10 found improvements that met the CID of 10.8 points. Of 7 studies reporting UPDRS IV scores, 5 found improvements meeting the CID of 2.3 points. Quality of life (QoL) was assessed in 6 studies using the 8- or 39-question version of the Parkinson's disease Questionnaire, and all reported improvements meeting the CID (10 points). Due to the nature of the data, it is not possible to give exact numbers for the frequency of adverse events. However, the findings seem to be in line with a previous report stating the majority of adverse events were related to the infusion system or surgical procedure rather than the drug. In conclusion, the large majority of studies have reported that Duodopa® is clinically effective in relieving the symptoms of advanced PD and improving QoL in comparison with conventional therapy. High-quality randomized trials with larger patient numbers will yield greater insights into the efficacy and safety of this treatment.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):718-27. doi: 10.1016/j.neurol.2008.11.017. Epub 2009 Jan 15. Rev Neurol (Paris). 2009. PMID: 19150100 Clinical Trial. French.
-
Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.J Neurol. 2018 Sep;265(9):2005-2014. doi: 10.1007/s00415-018-8951-3. Epub 2018 Jun 27. J Neurol. 2018. PMID: 29951701
-
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.Neurology. 2005 Jan 25;64(2):216-23. doi: 10.1212/01.WNL.0000149637.70961.4C. Neurology. 2005. PMID: 15668416 Clinical Trial.
-
[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(11):145-51. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID: 25629138 Review. Russian.
-
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.CNS Drugs. 2016 May;30(5):381-404. doi: 10.1007/s40263-016-0336-5. CNS Drugs. 2016. PMID: 27138916 Review.
Cited by
-
Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.Curr Neurol Neurosci Rep. 2016 Apr;16(4):34. doi: 10.1007/s11910-016-0635-8. Curr Neurol Neurosci Rep. 2016. PMID: 26898686 Review.
-
Update on the Management of Parkinson's Disease for General Neurologists.Parkinsons Dis. 2020 Mar 26;2020:9131474. doi: 10.1155/2020/9131474. eCollection 2020. Parkinsons Dis. 2020. PMID: 32300476 Free PMC article. Review.
-
Therapy for Parkinson's disease: what is in the pipeline?Neurotherapeutics. 2014 Jan;11(1):24-33. doi: 10.1007/s13311-013-0242-1. Neurotherapeutics. 2014. PMID: 24343458 Free PMC article. Review.
-
Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.Drugs Aging. 2019 Feb;36(2):103-113. doi: 10.1007/s40266-018-0624-5. Drugs Aging. 2019. PMID: 30556112
-
A mini review on pyridoacridines: Prospective lead compounds in medicinal chemistry.J Adv Res. 2015 Jan;6(1):63-71. doi: 10.1016/j.jare.2014.11.002. Epub 2014 Nov 15. J Adv Res. 2015. PMID: 25685544 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous